Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 4 3Phase 1 3Phase NA 2Phase EARLY_PHASE1 2Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Invasive Fungal Infections 1Hematologic Neoplasms 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Interventional × posaconazole × Clear all
NCT00750737 2016-09-29

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

M.D. Anderson Cancer Center

Phase 3 Completed
46 enrolled 6 charts
Other hematologic neoplasm

Invasive Fungal Infections, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡